Strategic partnerships Araceli has recent and high-profile collaborations with Idorsia and Okolab, plus a pending expansion into Switzerland. Target opportunities: co-development, joint marketing, and integrated imaging solutions with contract research organizations and pharmaceutical collaborators to accelerate drug discovery programs.

Global expansion Launches in Oregon and Switzerland signal an international growth trajectory. Sales opportunities exist in lab infrastructure, dynamic biology screening, and regional pharma accounts seeking ultra-high-content imaging and live-cell capabilities to scale screening campaigns.

Board and leadership New board member with financial leadership and governance experience and a notable scientific advisory addition indicate increased governance and strategic growth focus. Use this to position Araceli for larger funding rounds, strategic partnerships, and enterprise-level licensing deals.

Finance and momentum Seed funding secured with a track record of multi-million revenue potential suggests readiness for upsell of platforms and data services. Opportunities include tiered service agreements, data analytics subscriptions, and expansion of Endeavor platform licenses to larger biopharma customers.

Technical leverage Dual value proposition of rapid actionable imaging and AI-ready data enables sell-in to research teams prioritizing speed and predictive modeling. Target large labs and CROs with integrated workflows, accelerated decision timelines, and compatibility with existing tech stacks (MATLAB, Salesforce, NetSuite, etc.).